^[1] Estimations nationales de l’incidence et de la mortalité par cancer en France mé­tropolitaine entre 1990 et 2018. Volume 1 – Tumeurs solides. Santé publique France 2019

^[2] Farges O et al. The Theory and Practice of Pancreatic Surgery in France. Ann Surg. nov 2017;266(5):797­804.

^[3] Ferlay J et al. More deaths from pancreatic cancer than breast cancer in the EU by2017. Acta Oncol Stockh Swed. oct 2016;55(9­10):1158­60.

^[4] Sharon CE et al. Fourteen years of pancreatic surgery for malignancy among ACS­NSQIP centers: Trends in major morbidity and mortality. Surgery. 7 mai 2022; https://doi.org/10.1016/j.surg.2022.03.030

^[5] Sánchez ­Velázquez P et al. Benchmarks in Pancreatic Surgery:A Novel Tool for Unbiased Outcome Comparisons. Ann Surg. août 2019;270(2):211­8.

^[6] Raptis DA et al. Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Ann Surg. nov 2020;272(5):731­7.

^[7] Russell TB et al. Procedure ­specific morbidity of pancreatoduodenectomy: a sys­tematic review of incidence and risk factors. ANZ J Surg. juin2022;92(6):1347­55.

^[8] Thomas AS et al. Prevalence and Risk Factors for Pancreatic Insufficiency After Partial Pancreatectomy. J Gastrointest Surg [Internet]. 22 mars 2022 https://doi.org/10.1007/s11605-­022-­05302-­3

^[9] De Bruijn KMJ et al. New ­onset diabetes after distal pancreatectomy: a systema­tic review. Ann Surg. mai 2015;261(5):854­61.

^[10] Roeyen G et al. Expert opinion on management of pancreatic exocrine insuffi­ciency in pancreatic cancer. ESMO Open. févr 2022;7(1):100386.

^[11] Rahib L, et al. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA Netw Open. 1 avr 2021;4(4):e214708.

^[12] Bouvier AM et al. Focus on an unusual rise in pancreatic cancer incidence in France. Int J Epidemiol. 1 déc 2017;46(6):1764­72.

^[13] Mizrahi JD et al. Pancreatic cancer. Lancet Lond Engl. 27 juin 2020;395(10242): 2008­20.

^[14] Bengtsson A et al. The actual 5 ­year survivors of pancreatic ductal adenocar­cinoma based on real­world data. Sci Rep. 02 2020;10(1):16425.

^[15] Schmidt CM et al. Acinar Cell Carcinoma of the Pancreasin the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma. J GastrointestSurg. 3 oct 2008;12(12):2078.

^[16] DeMartel C et al. Epidémiologie du cancer du pancréas. I. In: Cancer du Pancréas. Arnette; 2010. p. 12­30. (Monographies de l’AFC).

^[17] Scott AT et al. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am. août 2019;99(4):793­814.

^[18] Souche R et al. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. sept 2020;9(9):2993.

^[19] Vaghaiwalla T et al. Surgical Management of Pancreatic Neuroendocrine Tu­ mors. Surg Oncol Clin N Am. avr 2020;29(2):243­52.

^[20] Teo RYA, et al. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. Surgery. 1 avr 2019;165(4):672­85.

^[21] de Ponthaud C et al. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs):What Every SurgeonNeeds to Know. Cancers. 27 nov 2021;13(23):5969.

^[22] Belfiori G et al. Vascular resection during pancreatectomy for pancreatic headcancer: A technical issue or a prognostic sign? Surgery. févr 2021;169(2):403­10.

^[23] Al­ Hawary MM et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the ameri­ can pancreatic association. Gastroenterology. janv 2014;146(1):291­304.e1.

^[24] Marion­ Audibert AM et al. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. AJR Am J Roentgenol. nov 2018;211(5):W217­25.

^[25] Raman SP et al . Cross­sectional imaging and the role of positron emission tomo­graphy in pancreatic cancer evaluation. Semin Oncol. févr 2015;42(1):40­58.

^[26] Glant JA et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocar­ cinoma? Surgery. oct2011;150(4):607­16.

^[27] Raman SP et al. Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer.AJR Am J Roentgenol. janv 2015;204(1):W37­42.

^[28] Neuzillet C et al. Pancreatic cancer: French clinical practice guidelines for dia­gnosis, treatment and follow­up. Dig LiverDis. déc 2018;50(12):1257­71.

^[29] De Angelis C et al. Endoscopic ultrasonography for pancreatic cancer: current and future perspectives. J Gastrointest Oncol. juin 2013;4(2):220­30.

^[30] Suto H et al. Prediction of local tumor control and recurrence ­free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy. J Surg Oncol. 15 mars 2022.

^[31] Tabata K et al. Prediction of pathological response to preoperative chemothe­rapy for pancreatic ductal adenocarcinoma using 2­-[18F]­-fluoro­-2­-deoxy­-d­-glucose positron­-emission tomography. Clin Radiol. juin 2022;77(6):436­42.

^[32] McGahan W et al. High SUVmax on routine pre­operative FDG­PET predicts early recurrence in pancreatic and peri­ampullary cancer. HPB. 30 janv 2022;S1365­182X(22)00038­7.

^[33] Ito T et al. clinical practice guidelines for gastroenteropancreatic neuroen­docrine neoplasms: diagnosis, treatment, and follow­up: a synopsis ­ JNETS 2021; 56:1033­44

^[34] Gupta V et al. Organ preserving pancreatic resections offer better long-­term conservation of pancreatic function at the expense of high perioperative major mor­bidity: a fair trade-­off for benign or low malignant potential pancreatic neoplasms — a single-­center experience. Langenbecks Arch Surg 2022 doi: 10.1007/s00423­022­ 02491­y

^[35] Asano Y et al. Clinical outcomes of organ ­preserving pancreatectomy for benign or low­grade malignant pancreatic tumors: A multicenter nationwide survey in Japan. J Hepato­Biliary­Pancreat Sci. 19 avr 2022

^[36] Bassi C et al. Value of regional lymphadenectomy in pancreatic cancer. HPB. juin 2005;7(2):87­92.

^[37] Tol JAMG et al. Definition of a standard lymphadenectomy in surgery forpancreatic ductal adenocarcinoma: A consensus statement by the International Stu­dy Group on Pancreatic Surgery (ISGPS). Surgery. sept 2014;156(3):591­600.

^[38] Kotb A et al. Meta-­analysis and trial sequential analysis of randomised controlled trials comparing standard versus extended lymphadenectomy in pancreatoduode­nectomy for adenocarcinoma of the head of pancreas. Langenbecks Arch Surg. mai 2021;406(3):547­61.

^[39] Orci LA et al. A meta­-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB. juill 2015;17(7):565­72.

^[40] Klaiber U et al. Randomized Trial of Pylorus ­Preserving vs. Pylorus ­Resecting Pancreatoduodenectomy: Long­Term Morbidity and Quality of Life. J Gastrointest Surg. févr 2020;24(2):341­52.

^[41] Hackert T et al. Pylorus Resection Does Not Reduce Delayed Gastric Emptying After Partial Pancreatoduodenectomy: A Blinded Randomized Controlled Trial (PRO­ PP Study, DRKS00004191). Ann Surg. juin 2018;267(6):1021­7.

^[42] Klaiber U et al. Meta-­analysis of delayed gastric emptying after pylorus ­pre­ serving versus pylorus­resecting pancreatoduodenectomy. Br J Surg. 28 févr 2018; 105(4):339­49.

^[43] de Rooij T et al. Minimally Invasive Versus Open Distal Pancreatectomy (LEO­ PARD): A Multicenter Patient ­blinded Randomized Controlled Trial. Ann Surg. janv2019;269(1):2­9.

^[44] Chowdappa R et al. Modified Heidelberg technique of pancreatic anastomosis postpancreaticoduodenectomy 10 years of experience. South Asian J Cancer. juin2019;8(2):88­91.

^[45] Hirono S et al. Modified Blumgart Mattress Suture Versus Conventional Inter­rupted Suture in Pancreaticojejunostomy During Pancreaticoduodenectomy: Rando­mized Controlled Trial. Ann Surg. févr 2019;269(2):243­51.

^[46] Clemente Getal. Pancreatico­Jejunostomy On Isolated Loop After Pancreati­co­Duodenectomy: Is It Worthwhile? J Gastrointest Surg Off J Soc Surg Aliment Tract. juin 2022;26(6):1205­12.

^[47] Shrikhande SV et al. Pancreatic anastomosis after pancreatoduodenectomy: A position statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. mai 2017;161(5):1221­34.

^[48] Kilambi R et al. Duct-­to­-mucosa versus dunking techniques of pancreaticoje­ junostomy after pancreaticoduodenectomy: Do we need more trials? A systematic review and meta­analysis with trial sequential analysis ­ J surg oncol https://doi.org/10.1002/jso.24986

^[49] Hai H et al. Duct­-to­-mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula following pancreaticoduodenec­tomy. Cochrane Database Syst Rev. 15 mars 2022;3:CD013462.

^[50] Hüttner FJ et al. Antecolic versus retrocolic reconstruction after partial pancrea­ticoduodenectomy. Cochrane Database Syst Rev. 11 janv 2022;1:CD011862.

^[51] van Hilst J et al. Minimally Invasive versus Open Distal Pancreatectomy for Duc­tal Adenocarcinoma (DIPLOMA): A Pan­European Propensity Score Matched Study.Ann Surg. janv 2019;269(1):10­7.

^[52] Hang K et al. Splenic vessels preserving versus Warshaw technique in spleenpreserving distal pancreatectomy: A systematic review and meta­analysis. Int J Surg Lond Engl. juill 2022;103:106686.

^[53] Kimura W et al. Spleen­ preserving distal pancreatectomy with conservation ofthe splenic artery and vein. Surgery. nov 1996;120(5):885­90.

^[54] Warshaw AL. Conservation of the spleen with distal pancreatectomy. Arch Surg Chic Ill 1960. mai 1988;123(5):550­3.

^[55] Korrel M et al. Short­-Term Outcomes After Spleen­ Preserving Minimally Invasive Distal Pancreatectomy With or Without Preservation of Splenic Vessels: A Pan­Euro­pean Retrospective Study in High­Volume Centers. Ann Surg. 2 juin 2021.

^[56] Miao Y et al. Management of the pancreatic transection plane after left (distal)pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. juill 2020;168(1):72­84.

^[57] Strasberg SM et al. Radical antegrade modular pancreatosplenectomy. Surgery. mai 2003;133(5):521­7.

^[58] Strasberg SM et al. Radical antegrade modular pancreatosplenectomy proce­dure for adenocarcinoma of the body and tail of the pancreas: ability to obtain nega­tive tangential margins. J Am Coll Surg. févr 2007;204(2):244­9.

^[59] Nießen A et al. State­of­the­art surgery for pancreatic cancer. Langenbecks Arch Surg. mars 2022;407(2):443­50.

^[60] Heidt DG et al. Total pancreatectomy: indications, operative technique, andpostoperative sequelae. J Gastrointest Surg Off J Soc Surg Aliment Tract. févr 2007;11(2):209­16.

^[61] Aleotti F et al. Total pancreatectomy sequelae and quality of life: results ofislet autotransplantation as a possible mitigation strategy. Updat Surg. août 2021; 73(4):1237­46.

^[62] Gilliland TM et al. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection. Nutrients. 7 mars 2017;9(3):E243.

^[63] Alexandre P. Haute Autorité de santé. 2019;25.

^[64] Strobel O et al. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. janv 2019;16(1):11­26.



^[65] Marchegiani G et al. Post pancreatectomy Acute Pancreatitis (PPAP): Definitionand Grading From the International Study Group for Pancreatic Surgery (ISGPS). Ann Surg. 1 avr 2022;275(4):663­72.

^[66] Wente MN et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. nov 2007;142(5):761­8.

^[67] Wente MN et al. Post pancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. juill 2007;142(1):20­5.

^[68] Bassi C et al. Postoperative pancreatic fistula: an international study group (IS­GPF) definition. Surgery. juill 2005;138(1):8­13.

^[69] Besselink MG et al. Definition and classification of chyle leak after pancreatic operation: A consensus statement by the International Study Group on Pancreatic Surgery. Surgery. févr 2017;161(2):365­72.

^[70] Bassi C et al. The 2016 update of the International Study Group (ISGPS) defi­nition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. mars2017;161(3):584­91.

^[71] Duarte Garcés AA et al. Reappraisal of post­pancreatectomy hemorrhage (PPH) classifications: do we need to redefinegrades A and B? HPB. août2018;20(8):702­7.

^[72] Eisenberg JD et al. Delayed Gastric Emptying After Pancreaticoduodenectomy: an Analysis of Risk Factors and Cost. J Gastrointest Surg Off J Soc Surg Aliment Tract. sept 2015;19(9):1572­80.

^[73] Fahlbusch T et al. Impact of pylorus preservation on delayed gastricemptying after pancreaticoduodenectomy­-analysis of 5,000 patients based on the German StuDoQ|Pancreas­Registry. Gland Surg. janv 2022;11(1):67­76.

^[74] Muzzolini M et al. Incidence and risk factors for Chyle leak after pancreatic sur­gery for cancer: A comprehensive systematic review. Eur J Surg Oncol. avr 2022;48(4):707­17.

^[75] Stoop TF et al. Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. Ann Surg Oncol. févr 2020;27(2):587­96.

^[76] Sabater L et al. Evidence­-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Ann Surg. déc 2016;264(6):949­58.

^[77] Othman MO et al. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract.2018;72(2):e13066.

^[78] Belyaev O et al. Early and late post-operative changes in the quality of life after pancreatic surgery. Langenbecks Arch Surg. avr 2013;398(4):547­55.

^[79] Phillips ME et al. Consensus for the management of pancreatic exocrine insuf­ficiency: UK practical guidelines. BMJ Open Gastroenterol. juin 2021;8(1):e000643.

^[80] Beger HG et al. New Onset of Diabetes and Pancreatic Exocrine Insufficiency After Pancreaticoduodenectomy for Benign and Malignant Tumors: A Systematic Review and Meta­analysis of Long-­term Results.Ann Surg. févr 2018;267(2):259­70.

^[81] Tseng DSJ et al. Pancreatic Exocrine Insufficiency in Patients With Pancreaticor Periampullary Cancer: A Systematic Review. Pancreas. mars 2016;45(3):325­30.

^[82] Bartel MJ et al. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig Liver Dis. 1 déc 2015;47(12):1013­20.

^[83] Roeyen G et al. The impact of pancreaticoduodenectomy on endocrine and exo­crine pancreatic function: A prospective cohort study based on pre­ and post opera­tive function tests. Pancreatology. 1nov 2017;17(6):974­82.

^[84] Shah KP et al. Long­-Term Assessment of Pancreatic Function After Pancreatec­tomy for Cystic Neoplasms. J Surg Res. mars 2020;247:547­55.

^[85] Pezzilli R et al. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Cancers. févr 2020;12(2):275.

^[86] Löhr JM et al. UEG evidence-­based guidelines for the diagnosis and therapy ofchronic pancreatitis (HaPanEU). United Eur GastroenterolJ. mars 2017;5(2):153­99.

^[87] Lv X et al. Impact of diabetes mellituson clinical outcomes of pancreatic can­cer after surgical resection: A systematic review and meta­-analysis. PloS One. 2017; 12(2):e0171370.

^[88] Stoop TF et al. Total pancreatectomy as an alternative to high­risk pancreato­jejunostomy after pancreatoduodenectomy: a propensity score analysis on surgical outcome and quality of life. HPB. 1 janv 2022;S1365­182X(21)01744­5.

^[89] Epelboym I et al. Quality of life in patients after total pancreatectomy is compa­rable with quality of life in patients who undergo a partial pancreatic resection. J Surg Res. mars 2014;187(1):189­96.